Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsFRA:CN2 93 EBITDA Margin % is 55.56% as of Mar. 2026, which is 54% above its 10-year median of 36.05. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €21.47 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 940 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 94.26% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Catalyst Pharmaceuticals EBITDA Margin % Related Terms
Catalyst Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CN2 vs CRNX, NAMS, RCUS: EBITDA Margin % Comparison
For the Biotechnology subindustry, Catalyst Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals (FRA:CN2) has a EBITDA Margin % of 55.56% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Catalyst Pharmaceuticals and its competitors. This is 54% above median its historical median of 36.05. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #54 out of 940 companies in the Biotechnology industry, placing it in the top 5.7%.
Is Catalyst Pharmaceuticals' EBITDA Margin % too high?
Catalyst Pharmaceuticals' current EBITDA Margin % of 55.56% is 54% above median its 10-year median of 36.05. Based on the distribution chart, Catalyst Pharmaceuticals ranks #54 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' EBITDA Margin % compare to CRNX and NAMS?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #54 out of 940 companies for EBITDA Margin %. This places Catalyst Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current EBITDA Margin % is 55.56%, which is 54% above median its own 10-year median of 36.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Modestly Overvalued. The stock's GF Value™ is €21.47, compared to a current price of €27.30 — trading 27.2% above its estimated fair value. The current EBITDA Margin % is 55.56%, which is 54% above median its 10-year median of 36.05. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current EBITDA Margin % is 55.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of €27.30 is trading 27.2% above its estimated GF Value™ of €21.47.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for FRA:CN2:
EBITDA Margin %: 55.56% (54% above median its 10-year median of 36.05)
GF Value™: €21.47 vs. price of €27.30 (27.2% above fair value)
No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score
Get the complete analysis for FRA:CN2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CN2 has been successfully added to your 
